Table 2.
n | ACh | n | SNP | |||
---|---|---|---|---|---|---|
pEC50 (M) | R max (%) | pEC50 (M) | R max (%) | |||
Treatment | ||||||
Control | 6 | −7.20 ± 0.15 | 93 ± 12 | 5 | −8.68 ± 0.15 | 96 ± 2 |
Pyrogallol | 5 | −6.77 ± 0.07 | 50 ± 4# | 5 | −8.48 ± 0.09 | 100 ± 2 |
Pyrogallol + tocomin 10−4 mg/mL | 5 | −7.19 ± 0.13 | 80 ± 3∗ | 5 | −8.34 ± 0.16 | 105 ± 5 |
P + T3 (α + δ + γ) + (α-TC) 10−4 mg/mL | 5 | −7.02 ± 0.11 | 73 ± 2∗ | 4 | −8.49 ± 0.17 | 102 ± 2 |
P + T3 (α + γ) 10−4 mg/mL | 6 | −6.86 ± 0.29 | 65 ± 6# | 5 | −8.20 ± 0.21 | 102 ± 1 |
P + T3 (α + δ + γ) 10−4 mg/mL | 3 | −6.57 ± 0.23 | 61 ± 13# | 5 | −8.12 ± 0.08 | 103 ± 2 |
Tocotrienol isomers and α-tocopherol were present in the proportions found in tocomin (i.e., is α-T3- 20%, δ-T3 10%, and γ-T3 50% and α-TC 20%).
#Significantly different to control p < 0.05.
∗Significantly different to pyrogallol p < 0.05.
Sidak's multiple comparison test.